Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB)

Journal of Nanobiotechnology

Yehuda Zeiri²  Zeev Karpas²  Raya Zach¹  Paz Elia¹  Hagit Cohen³  Hagit Sela² 

[1] Department of Biomedical Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel;Department of Chemistry, NRCN, Beer-Sheva 8419001, Israel;The State of Israel Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Beer-Sheva Mental Health Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel

关键词: LA-ICP-MS;    ICP-MS;    Blood-brain barrier;    Penetration;    Biokinetics;    Rat;    Gold nanoparticles;   

Others  :  1231705
DOI  :  10.1186/s12951-015-0133-1

 received in 2015-06-27, accepted in 2015-10-06,  发布年份 2015

【 摘 要 】

Background

The blood brain barrier (BBB) controls the brain microenvironment and limits penetration of the central nervous system (CNS) by chemicals, thus creating an obstacle to many medical imaging and treatment procedures. Research efforts to identify viable routes of BBB penetration have focused on structures such as micelles, polymeric nanoparticles and liposomes as drug carriers, however, many of them failed to provide unequivocal proof of BBB penetration. Here we proved that gold nanoparticles (AuNPs) penetrate the BBB in rats to reach brain regions.

Results

Injection of AuNPs to the abdominal cavity of rats resulted in levels of gold found in blood, urine, brain regions and body organs. After perfusion the concentration of gold in brain regions diminished dramatically indicating that most of the gold was in venous blood and not in the brain tissues. Injection of Na, K or Ca ion channel blockers reduced BBB penetration by half. A biological half-life of 12.9 ± 4.9 h was found for the gold nanoparticles. Possible mechanisms for the transport of AuNPs through the BBB are discussed.

Conclusions

BBB penetration by AuNPs is spontaneous without the application of an external field. A major amount of gold resides in blood vessels therefore perfusion required. Ion channel blockers can be used to control the transport of AuNPs.

【 授权许可】

   
2015 Sela et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

【 参考文献 】

• [1]Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int. 2004; 45:545-552.
• [2]Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010; 37:13-25.
• [3]Nag S, Begley DJ. Blood-brain barrier, exchange of metabolites and gases. In: Kalimo H, editor. Cerebrovascular diseases. Basel:ISN Neuropath Press; 2005. p. 22–9.
• [4]Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009.
• [5]Jain KK. Nanobiotechnology-based strategies for crossing the blood–brain barrier. Nanomedicine. 2012; 7:1225-1233.
• [6]Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009; 23:35-58.
• [7]Jain KK. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener Dis. 2007; 4:287-291.
• [8]Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood–brain barrier. Int J Nanomed. 2014; 9:795-811.
• [9]Gabathuler R. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiol Dis. 2010; 37:48-57.
• [10]Nagashima T, Ikeda K, Wu S, Kondo T, Yamaguchi M, Tamaki N. The mechanism of reversible osmotic opening of the blood–brain barrier: role of intracellular Ca ++ ion in capillary endothelial cells. Acta Neurochir. 1997; 70:231-233.
• [11]Smith CA, Mainprize TG, Hynynen K, Rutka JT. Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRI-guided focused ultrasound. Nanomed Nanotechnol Biol Med. 2012; 8:1133-1142.
• [12]Jain PK, Huang X, El-Sayed IH, El-Sayed MA. Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. Acc Chem Res. 2008; 41:1578-1586.
• [13]Key J, Leary JF. Nanoparticles for multimodal in vivo imaging in nanomedicine. Int J Nanomed. 2014; 9:711-726.
• [14]Shilo M, Motiei M, Panet H, Popovtzer R. Transport of nanoparticles through the blood–brain barrier for imaging and therapeutic applications. Nanoscale. 2014; 6:2146-2152.
• [15]Hainfeld JF, Smilowitz HM, O’Connor MJ, Dilmanian FA, Slatkin DN. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine. 2013; 8:1601-1609.
• [16]Joh DY, Sun K, Stangl M, Al Zaki A, Murty S, Santoiemma PP, Davis JJ, Baumann BC, Alonso-Basanta M, Bhang D, Kao GD, Tsourkas A, Dorsey JF. Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization. PLOS One. 2013;8:62425–35.
• [17]Kwon SG, Hyeon T. Colloidal chemical synthesis and formation kinetics of uniformly sized nanocrystals of metals, oxides, and chalcogenides. Acc Chem Res. 2008; 41:1696-1709.
• [18]Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 2004; 104:293-346.
• [19]Weiss PS. Functional molecules and assemblies in controlled environments: formation and measurements. Acc Chem Res. 2008; 41:1772-1781.
• [20]Murphy CJ, Gole AM, Stone JW et al.. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res. 2008; 41:1721-1730.
• [21]Elia P, Zach R, Hazan S, Kolusheva S, Porat Z, Zeiri Y. Green synthesis of gold nanoparticles using plant extracts as reducing agents. Int J Nanomed. 2014; 9:4007-4021.
• [22]Madani F, Lindberg S, Langel U, Futaki S, Graslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011.
• [23]Ritchie HE, Ababneh DH, Oakes DJ, Power CA, Webster WS. The teratogenic effect of dofetilide during rat limb development and association with drug-induced bradycardia and hypoxia in the embryo. Birth Defect Res (Part B). 2013;98(2):144–53.
• [24]Lenkowski PW, Ko SH, Anderson JD, Brown ML, Patel MK. Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci. 2004; 21(5):635-644.
• [25]Iannetti P, Spalice A, Parisi PP. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia. 2005;46(6):967–69.
• [26]Ayush VA, Oktay UO, Yuhua HY et al.. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater. 2008; 7:588-595.
• [27]Lin J, Zhang H, Chen Z, Zheng Y. Penetration of lipid membranes by gold. nanoparticles: insights into cellular uptake, cytotoxicity, and their relationship. ACS Nano. 2010; 4:5421-5429.
• [28]Wang T, Bai J, Jiang X, Nienhaus GU. Cellular uptake of nanoparticles by membrane penetration: a study combining confocal microscopy with FTIR spectroelectrochemistry. ACS Nano. 2012; 6:1251-1259.
• [29]Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: size matters. J Nanobiotechnol. 2014; 12:5. BioMed Central Full Text
• [30]Yuan H, Wilson CM, Li S, et al. Optically enhanced blood-brain-barrier crossing of plasmonic-active nanoparticles in preclinicalbrain tumor animal models. SPIE. 2014; Proceedings Paper.
• [31]Shilo M, Sharon A, Baranes K, Motiei M, Lellouche JPM, Popovtzer R. The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell model. J Nanobiotechnol. 2015; 13:19. BioMed Central Full Text
• [32]Boda D, Henderson D, Busath DD. Monte Carlo study of the effect of ion and channel size on the selectivity of a model calcium channel. J Phys Chem B. 2001; 105:11574-11577.
• [33]Nimigean CM, Allen TW. Origins of ion selectivity in potassium channels from the perspective of channel block. J Gen Physiol. 2001; 137(5):405-413.
• [34]Kang Y, Zhang Z, Shi H et al.. Na + and K + ion selectivity by size-controlled biomimetic graphene nanopores. Nanoscale. 2014; 6:10666-10672.
• [35]Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1(3):223–36.
• [36]Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev. 2010; 64(2):328-363.
• [37]Palant CE, Duffey ME, Mookerjee BK, Ho S, Bentzel CJ. Ca 2+ regulation of tight-junction permeability and structure in Necturus gallbladder. Am J Physiol. 1983; 245(3):C203-C212.
• [38]Gonzalez-Mariscal L, Chavez de Ramirez B, Cereijido M. Tight junction formation in cultured epithelial cells (MDCK). J Membr Biol. 1985;86(2):113–25.
• [39]Bart J, Willemsen AT, Groen HJ et al.. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. NeuroImage. 2003; 20(3):1775-1782.
• [40]Hsiao P, Sasongko L, Link JM et al.. Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther. 2006; 317(2):704-710.
• [41]Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen J, Friis S. L-type calcium channel blockers and Parkinson’s disease in Denmark. Ann Neurol. 2010; 67(5):600-606.
• [42]Gendelman HE, Ding S, Gong N et al.. Monocyte chemotactic protein-1 regulates voltage-gated K + channels and macrophage transmigration. J Neuroimmune Pharmacol. 2009; 4(1):47-59.
• [43]Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold solutions. Nat Phys Sci. 1973; 241:20-22.